# Lineage Cell Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lineage Cell Therapeutics, Inc.). ## Overview Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or off-the-shelf, cell therapies for serious ophthalmic and neurological diseases. It uses a proprietary pluripotent-cell platform, AlloSCOPE, to design, manufacture, and test specialized human cells intended to replace or support damaged tissue, often through collaborations with larger pharmaceutical partners. ## Products & services • OpRegen® (RG6501) retinal pigment epithelial cell therapy • OPC1 oligodendrocyte progenitor cell therapy • ReSonance (ANP1) auditory neuron progenitor cell therapy • AlloSCOPE cell engineering and cGMP manufacturing platform • Collaborative development and licensing of cell therapy assets - **Clinical-stage cell therapies** (20%) — Lead therapeutic candidates in human trials for ophthalmic and neurological diseases. - **Preclinical cell therapies** (10%) — Earlier-stage programs being advanced through internal development or partnerships. - **Collaborative development revenue** (60%) — Revenue from research, development, and license collaborations with partners such as Roche. - **Platform and manufacturing capabilities** (10%) — Cell engineering, banking, formulation, and cGMP production capabilities used across programs. - OpRegen® (RG6501) for geographic atrophy secondary to AMD - OPC1 for spinal cord injury recovery - ReSonance (ANP1) for auditory neuropathy - AlloSCOPE pluripotent cell engineering platform - cGMP cell banking, formulation, and delivery capabilities - Partnered cell therapy development and licensing ## Customers Lineage Cell Therapeutics sells primarily to pharmaceutical and biotech collaborators rather than end patients, with Roche/Genentech being the most visible partner in its lead program. Its therapies are ultimately aimed at patients with geographic atrophy, spinal cord injury, and auditory neuropathy, but near-term value creation comes from licensing, collaboration, and development milestones. Government agencies have also supported some programs through grants. - **Pharmaceutical collaboration partners** (primary) — Buy development rights, access to assets, and platform expertise to advance cell therapy programs. - **Strategic biotech partners** (secondary) — Partner on preclinical or early clinical assets where shared development reduces risk and cost. - **Government and grant agencies** (secondary) — Provide non-dilutive funding for research and development of selected programs. - **Patients in target indications** (emerging) — The eventual end users of the therapies, especially in ophthalmology and neurology. - Roche/Genentech for OpRegen development and commercialization rights - William Demant Invest for the ReSonance auditory program - Government grant providers supporting selected R&D programs - Future pharma partners seeking cell-therapy assets and platform access - Patients with AMD, spinal cord injury, and auditory neuropathy are the end market ## Geography The company is headquartered in the United States, but its development footprint is international through collaborations and operations tied to partners and facilities abroad. The reports specifically note facilities in Israel and a worldwide collaboration with Roche, which makes the business exposed to cross-border regulatory, operational, and geopolitical risks. Because it is still clinical-stage, geography matters more for where trials, manufacturing, and partner activity occur than for commercial sales. - United States headquarters and primary corporate base - Israel facilities support part of the operating footprint - Worldwide Roche collaboration expands OpRegen development reach - International partner structure increases regulatory and execution complexity - No country-level revenue disclosure was provided in the excerpts ## Strategy Lineage’s strategy is to use its AlloSCOPE platform to create a pipeline of related allogeneic cell therapy assets that can be advanced internally or partnered. The company is prioritizing programs with clear clinical and commercial potential, while using collaborations to share development cost, broaden expertise, and improve the odds of success. It also emphasizes scalable manufacturing, since reproducibility and supply are central to any future commercialization. - **Advance OpRegen in partnership with Roche** (short-term) — The lead ophthalmology program is the most advanced asset and a key source of validation. - **Scale and de-risk manufacturing** (medium-term) — Reliable, reproducible cell production is essential for clinical supply and eventual commercialization. - **Expand the partnered pipeline** (medium-term) — Additional collaborations can fund development and increase the value of the platform. - Advance OpRegen through Roche collaboration - Progress OPC1 and ReSonance toward clinical value inflection - Use partnerships to reduce capital intensity and share risk - Leverage AlloSCOPE to create repeatable cell-therapy assets - Build scalable cGMP manufacturing for future commercialization ## Risks The company faces the classic risks of clinical-stage biotech: uncertain trial outcomes, regulatory delay, and dependence on third-party partners for development and commercialization. Its cell-therapy model adds manufacturing and supply-chain complexity, including the risk that cell lines, delivery devices, or infectious contamination issues could disrupt programs or force costly remediation. Geopolitical and personnel risks are also meaningful because operations include facilities in Israel and the business depends on specialized scientific talent. - **Clinical development failure** [high] — Programs are still in early-stage testing and may not demonstrate sufficient safety or efficacy. - **Manufacturing and cell-bank contamination** [high] — Allogeneic cell therapies depend on stable cell lines and reproducible cGMP production. - **Regulatory uncertainty for novel cell therapies** [high] — There is limited precedent for pluripotent stem cell-derived and iPSC-derived approvals. - **Third-party device and supply dependence** [medium] — Specialized delivery systems may be needed and could be unavailable or fail performance standards. - **Geopolitical disruption in Israel** [medium] — Facilities and employees in Israel may be affected by regional conflict and mobilization. - Clinical trials may fail to show safety or efficacy - Regulatory approval is uncertain for novel pluripotent cell therapies - Manufacturing variability can disrupt supply and trial timelines - Delivery devices and combination-product issues can add delay and cost - Infectious contamination could compromise foundational cell banks - Israel operations and key staff are exposed to regional conflict risk ## Accounting The most important accounting issue is revenue recognition under collaborative agreements, since reported revenue may depend on milestones, performance obligations, and timing judgments rather than product sales. Investors should also watch impairment testing for intangible assets and the classification of warrants, both of which can create volatility in reported results. As a clinical-stage company, it likely has limited revenue and significant judgment around estimates, making quarter-to-quarter comparability sensitive to collaboration timing and non-cash valuation changes. - **Revenue recognition under collaborative agreements** — Affects reported revenue timing and comparability - **Intangible asset impairment** — Can materially affect earnings and balance sheet value - **Warrant liability or equity classification** — Can create non-cash gains or losses - **Deferred taxes and tax reserves** — Affects tax expense and net loss - Collaborative agreement revenue depends on milestone and performance timing - Intangible asset impairment can affect reported earnings - Warrant classification may create equity or liability volatility - Deferred tax assets and tax reserves rely on management estimates - Quarterly results may be lumpy due to collaboration accounting --- *Last updated: 2026-04-28T20:23:05.309588+00:00*